Mill Creek Capital Advisors LLC Sells 390 Shares of Novo Nordisk A/S (NYSE:NVO)

Mill Creek Capital Advisors LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 12.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,734 shares of the company’s stock after selling 390 shares during the quarter. Mill Creek Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $326,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. RIA Advisory Group LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter worth $281,000. Natixis Advisors LLC raised its position in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the last quarter. First Long Island Investors LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter worth $3,715,000. Birchcreek Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 8.3% during the third quarter. Birchcreek Wealth Management LLC now owns 2,542 shares of the company’s stock worth $303,000 after acquiring an additional 195 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC increased its holdings in Novo Nordisk A/S by 4.5% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 3,470 shares of the company’s stock valued at $413,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 3.4 %

NYSE:NVO opened at $101.74 on Monday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $456.56 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42. The stock has a 50-day moving average price of $118.58 and a two-hundred day moving average price of $129.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.